Evidence map›Paper›PMID 42582756›Full record

ReviewFrontiers in immunology2026

MuSK myasthenia gravis: from antigen-antibody to clinical translation.

Xinyue Zhou, Jing Zhang, Haiyan Dong, Xinxin Cui, Hanxin Zhang, Mengdi Zhang, Ruichen Liu, Qian Liu, Jia Hu, Jing Liu and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xinyue Zhou *Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Jing Zhang *Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Haiyan DongDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Xinxin CuiDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Hanxin ZhangDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Mengdi ZhangDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Ruichen LiuDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Qian LiuDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Jia HuDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Jing LiuDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Yingna ZhangDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Xue ZhaoDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Ting ChangDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Zhe RuanDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Junhong YangDepartment of Encephalopathy, First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Jie LvDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Feng GaoDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-MuSK antibody-positive myasthenia gravis (MuSK-MG) is characterized by severe and potentially life-threatening weakness. Anti-MuSK antibodies are key pathogenic drivers of this disorder. This review provides a comprehensive summary of the current state-of-the-art with respect to the understanding of MuSK and its role in MuSK-MG. MuSK, a receptor tyrosine kinase, is essential at the neuromuscular junction, where it forms an agrin-LRP4-MuSK tripartite functional complex that initiates and maintains agrin-induced acetylcholine receptor clustering at the postsynaptic membrane. Although anti-MuSK antibodies encompass all IgG subclasses (IgG1-4), IgG4 is the predominant pathogenic subclass.

Indexed as

AutoantibodiesMyasthenia GravisReceptor Protein-Tyrosine KinasesReceptors, CholinergicAnimalsHumansImmunoglobulin GLDL-Receptor Related ProteinsNeuromuscular JunctionAutoantibodiesImmunoglobulin GLDL-Receptor Related ProteinsLRP4 protein, humanMUSK protein, humanReceptor Protein-Tyrosine KinasesReceptors, Cholinergicantigen–antibodyautoimmune diseasedetection and treatmentMuSKmyasthenia gravis

Identifiers

PMID42582756
PMCPMC13458558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.